Welcome to California Department of Public Health's California COVID-19 Vaccination Program Friday Provider Office Hours



Friday, February 18, 2022



Provider Office Hours Q&A

During today's session, please use the **Q&A panel** to ask your questions so our subject matter experts can respond directly.







Housekeeping

Reminder to Panelists:



Please mute yourself when not speaking.

Please monitor the Q&A panel for questions you may be able to answer.

Reminder to Attendees:



Today's session is being recorded. Access today's slides and archived presentations at: https://eziz.org/covid/education/



If you have technical difficulties, please contact Rachel.Jacobs@cdph.ca.gov



Agenda: Friday, February 18, 2022

No.	Item	Speaker	Time (AM)	
1	Welcome & Announcements	Leslie Amani (Moderator)	9:00 – 9:05	
2	SMARTER Plan California	Robert Schechter, M.D. (CDPH)	9:05 – 9:10	
3	Pediatric Update	Robert Schechter, M.D. (CDPH)	9:10 – 9:15	
4	Vaccine Administration	Elizabeth Reosti (CDPH)	9:15 – 9:20	
5	Clinical Update	Caterina Liu, M.D. (CDPH)	9:20 – 9:25	
	Q&A		9:25 – 9:35	
6	Storage & Handling	Kate McHugh (CDPH)	9:35 – 9:40	
7	Vaccine Management	Eric Norton (My Turn) and Claudia Aguiluz (CDPH)	9:40 – 9:50	
8	Wrap Up & Resources	Leslie Amani (Moderator)	9:50 – 10:00	
Q&A				



Announcements

Leslie Amani, CDPH



Archived: Crucial COVID-19 Conversations Webinar

Using Social Media to Effectively Communicate about COVID-19 Vaccines

Watch here | View slides here



Understanding the Social Media Algorithm

Consistency is key.

Posting frequently with consistent messaging will increase your organic reach, placing your content in front of more of your followers.

Visuals, Visuals, Visuals,

All platforms will prioritize content that includes media. Photos and videos are preferred.

Make it personal.

Share your stories of those within your close circle who were hesitant. Share your "why"

Avoid spamming.

Too many tags, sharing posts from only one source, and excessive posting can push your content to the bottom of friends' news feeds.

Be timely. Provoke emotion.

Content that moves and impacts will typically make people laugh, cry, or scared. Be authentic.

Re-define community.

Where people work, play, and pray. What communities are you part of?







Pfizer COVID-19 Vaccine Medical Updates & Training Sessions

Date & Time (linked)	Password			
Tuesday, February 22 - 12PM	MMeBHKrM326			
Wednesday, February 23 - 9AM	NgBarUWa228			
Thursday, February 24 - 9AM	nMfj6BJEy32			
Tuesday, March 1 - 12PM	svU8YkF58Qc			
Wednesday, March 2 - 9AM	3jJ2WJMgeb8			
More sessions listed! NOTE: All times listed here are P.S.T.				

For providers and immunization staff personnel. Please attend one of these sessions!

Topics include:

- Introduction of new Controlant Temperature Monitoring Device
- Use of each vaccine presentation, including storage, handling, preparation, and administration for:
 - Ages 5 through 11 Years
 - Ages 12 Years and Older



Take the VA58 Misinformation 101 Training!

The VA58 Trust & Safety Team is hosting a live training to help LHJs, MCEs, and Providers understand and respond to misinformation related to COVID-19 vaccines circulating within Californian communities.

WHAT IS IT?


 This interactive, hour-long, live training will provide partners with a better understanding of what misinformation is, how it impacts people and the broader vaccination effort, and how to respond to it.

WHEN IS IT?


The training will take place on March 3rd from 12:30-1:30pm PST via Zoom.
 Please email rumors@cdph.ca.gov if you don't currently have the invite but would like to attend.


WHY TAKE IT?

 Conflicting information about the COVID-19 vaccines plays a big role in vaccine hesitancy, and the VA58 Campaign needs your support slowing its spread so that we can vaccinate all 58!









Love Letters Social Graphics





Missed Vaccination & Wastage Job Aid

- Avoid missed opportunities for vaccination
- Vaccinate family members or friends who accompany patients to medical visits even if they are not established patients at the practice.
- Follow clinical best practices to maximize vaccination
 - Assess immunization status at every visit
 - Make a strong recommendation for immunization

Missed Vaccination Opportunities & Wastage



California COVID-19 Vaccination Program

Never miss a vaccination opportunity because of fear of vaccine wastage! Do your best to follow clinical and inventory management best practices for vaccination to maximize vaccinations and minimize dose wastage where possible.

Vaccine wastage is expected, may be unavoidable, and will even increase as vaccine rollout continues because

- more providers, including smaller provider sites, are now receiving vaccine;
- vaccine continues to be available only as multi-dose vials: and
- vials must often be punctured without using the full number of doses printed on the label

Never Miss a Vaccination Opportunity

CDC Guidance: Vaccinate every eligible person who presents at a Punctured vials must be used within: vaccination site-even if it means puncturing a vial at the end of

Several studies have shown eliminating missed opportunities could increase vaccination coverage by up to 20% (Pink Book, "System-Based Barriers"). Follow these tips:

- Vaccinate family members or friends who accompany patients to medical visits even if they are not established patients at the vaccinating practice.
- Continue <u>outreach to employers or other community</u> partners that have a large membership or network to arrange vaccination events for primary or booster doses.
- Follow both clinical and inventory management best practices for vaccination to maximize vaccination and

- Pfizer (5-11Y orange cap) Pfizer Tris-Sucrose 12Y+ (gray cap)

- Pfizer (12Y+ purple cap)
- · Johnson & Johnson's Janssen (must be at 2-8 degrees Celsius)

Johnson & Johnson's Janssen (at room

Tips to Reduce Wastage

- Follow guidance in <u>CDC Toolkit</u> and <u>CDC summarized guidance</u> to reduce waste in COVID-19 vaccine storage, transport, handling, and administration in accordance with the CDC and manufacturer's guidance.
- . If there are a substantial number of expiring vials, contact your local health department and other partners to discuss redistribution of vaccine to areas of need.
- Work with your local health department in advance to determine thresholds for the number of vials in danger of being wasted that would trigger a call for guidance.
- Make every effort to coordinate the number of vials needed with the anticipated number of patients when preparing for daily clinics to help reduce over-thawing of vaccine.

California COVID-19 Vaccination Program


IMM-1379 (2/16/22)



Stay informed! Provider Resources on eziz.org/covid

Frequent Content Updates:

- Alerts
- Program Enrollment
- My Turn Onboarding
- Reporting Requirements
- Patient Resources
- Archived Communications
- Education & Support Materials
- More to explore!





COVID-19 Vaccine Provider FAQs

- Answers to provider questions
- Updated weekly: last updated 2/17/2022
- Currently in its 59th iteration!



Q: How many vaccine doses are recommended for persons who received the Janssen (J&J) vaccine as their primary vaccine?

A: A second dose of an mRNA vaccine is recommended four weeks after a recipient's first dose of Janssen (J&J) vaccine. A single booster dose of an mRNA vaccine is recommended at least 2 months after the second (additional) dose, for a total of 3 doses. For further information, please visit CDC Interim Clinical Considerations.



Q: Should COVID-19 vaccine Providers dispose of their expiring Janssen (J&J) vaccine?

A: Not at this time as J&J has requested a shelf-life extension for its Janssen vaccine for an additional 5 months. The FDA is expected to announce the ruling this month (February).

California COVID-19 Vaccination Program Provider FAQs

For Prospective, Newly Enrolled, and Current California COVID-19 Vaccine Providers.

Providers may also visit California COVID-19 Vaccination Program for Information and updates.

Directions: Click on a category to be directed to related FAQs.

Contents

New and Updated FAQs	2
Pediatric Providers	3
Vaccine Program Management	ε
Provider Enrollment	8
Ordering	9
Distribution/Redistribution	10
Vaccine Administration	12
Additional Doses for Immunocompromised	17
Booster Doses	18
Vaccine Storage & Handling	20
Inventory	23
Reporting	23
Costs & Reimbursement	25
Communication Resources	26

Provider FAQs on EZIZ, Updated Weekly





COVID-19 Vaccination Program Webinars and Training for Providers

Week of February 21, 2022

Note: Calendar subject to change

	Monday 2/21	Tuesday 2/22	Wednesday 2/23	Thursday 2/24	Friday 2/25
myCAvax					Provider Office Hours 9:00 am – 10:00 am PW: Immunize!
Combined Office Hours and Events	Holiday	Pfizer BioNTech COVID-19 Vaccine Training & Education* 12:00 pm – 1:00 pm PW: MMeBHKrM326	Pfizer BioNTech COVID-19 Vaccine Training & Education* 9:00 am – 10:00 am PW: NgBarUWa228	Pfizer BioNTech COVID-19 Vaccine Training & Education* 9:00 am – 10:00 am PW: nMfj6BJEy32	

^{*} Pfizer BioNTech COVID-19 Vaccine Training & Education topics vary by day, and include the latest information and recent changes, vaccine use, storage & handling, preparation & administration, recent medical updates, healthcare provider resources, and a Q&A session

View On Demand

- What's New in myCAvax for Release 21 (v. 1/18/22)
- Intro to My Turn Onboarding (v. 1/4/22)
- <u>Latest Features in My Turn</u> (* Requires My Turn Login)

- Provider 101 Account Enrollment: Section A: Organization Application (v. 10/21/21)
- Provider 101 Account Enrollment: Section B: Location Application (v. 10/21/21)
- <u>Provider Office Hours and MCE Office Hours</u>
 <u>Archived Sessions</u>

- Recording a Transfer/Redistribution Report (v. 12/20/21)
- Recording a Shipment Incident (v. 12/20/21)

- Recording an Excursion Event (v. 12/20/21)
- Recording a Waste Event (v. 12/20/21)

Help

Website: www.eziz.org/covid, FAQs

General email: covidcallcenter@cdph.ca.gov

CDPH Provider Call Center: 1-833-502-1245, 8am-6pm

My Turn email: myturnonboarding@cdph.ca.gov

myCAvax Help Desk Email: myCAvax.HD@accenture.com

Phone: (833) 502-1245



SMARTER Plan California

Robert Schechter, M.D., CDPH



California's COVID-19 SMARTER Plan



SMARTER stands for:

- Shots Vaccines are the most powerful weapon against hospitalization and serious illness.
- Masks Properly worn masks with good filtration help slow the spread of COVID-19 or other respiratory viruses.
- Awareness We will continue to stay aware of how COVID-19 is spreading, evolving variants, communicate clearly how people should protect themselves, and coordinate our state and local government response.
- Readiness COVID-19 is not going away, and we need to be ready with the tools, resources and supplies we will
 need to quickly respond and keep public health and the healthcare system well prepared.
- Testing Getting the right type of tests—PCR or antigen—to where they are needed most. Testing will help CA minimize the spread of COVID-19.
- Education California will continue to work to keep schools open and children safely in classrooms for in-person instruction.
- Rx Evolving and improving treatments will become increasingly available and critical as a tool to save lives.

The SMARTER Plan is not just for COVID-19. We can use these strategies and systems for future emergencies.



SMARTER Plan Resources





SMARTER Plan PDF

SMARTER Plan Toolkit

SMARTER Plan on CA All



Pediatric Update

Robert Schechter, M.D., CDPH



Vaccine coming soon-*ish* for Under-5s!

2/1: Pfizer BioNTech submitted EUA application to FDA

2/6-7: Media reports, HHS Provisional Timelines

2/11: Hold requested for EUA Application



Disparities in children 5-to-11-years-old

A similar pattern, but more extreme than older age groups.

1+ dose coverage estimates range from 5%-to-78%







Figure 3

Twice The Share Of Parents Of Children Ages 5-11 Now Say Their Child Has Been Vaccinated, Fewer Report Wanting To Wait And See

Thinking about your child between the ages of 5 and 11, have they received at least one dose of a COVID-19 vaccine, or not? If not, do you think you will get them vaccinated...?



NOTE: Among parents or guardians of children between the ages of 5 and 11. Jul.-Oct. 2021 question wording: "Once there is a COVID-19 vaccine authorized and available for your child's age group, do you think you will...?" See topline for full question wording. SOURCE: KFF COVID-19 Vaccine Monitor

KFF COVID-19 Vaccine Monitor



Vaccine coming soon for Under-5s! But where will they get it?

- Pharmacies with a diminished role
- More primary care providers needed
 - Medical home optimal as a trusted source of care
 - Can counsel hesitant families
 - Barriers frequently cited to enrollment: staffing, others...
 - Recruitment efforts continue but will take time to build a fuller network
- Who can bridge the gaps in the meantime?




Additional local primary care providers needed...

American Academy of Pediatrics

Important Alert - January 28, 2022

"...Please join the pediatricians who are already administering the COVID-19 vaccine in their clinics; it is the current standard of care. We hope that we can increase the number of providers giving these vaccines so that we can finally move on from this pandemic. Once again, our children are relying on us, and we must take the lead to make sure they are protected."





Vaccine Administration Data


Elizabeth Reosti, CDPH



Vaccine Administration Summary

as of February 14, 2022


Total Doses Administered: 70,728,315






Trends in Vaccine Administration

as of February 14, 2022









Booster* Vaccinations

as of February 14, 2022





% Eligible, Has Received Booster

**Note that 12-17 is the newest eligible age group for booster vaccination.

^{**24,498,076} individuals, 12+ years of age, and J&J + 2 months or mRNA + 5 months




-0%

^{*}Includes Additional Doses


Booster* Vaccinations

as of February 14, 2022




23% gap in booster vaccinations between Q1 and Q4

+0%



% Eligible, Has Received Booster





5-to-11 Vaccinations


as of February 14, 2022

VEM/HPI Q4 vs Q1 Equity Gap

+ 1%

- 33% gap between Q4 and Q1 youth
- Q4 youth 3x more likely to be vaccinated than their Q1 counterparts

Percent Fully Vaccinated Among 5 to 11 Year Olds by VEM, Since Nov 1, 2021





Data Summary

as of February 14, 2022

Statewide Trends – modest increase, rates slowing

70.7 Million doses administered

-25% change in new doses from previous week

Equity Metrics - no change

23% gap between Q1 and Q4 boosters

33% gap between Q1 and Q4 5-11-year-olds

Ongoing Work

- Age-Race-County Rates
- Improved Geographic Data (Region)
- Pediatric Access (VFC)
- Race/Ethnicity Quality Improvement



Clinical Update

Caterina Liu, M.D., CDPH



Upcoming FDA Vaccines and Related Biological Products Advisory Committee (VRBPAC) Meetings



- VRBPAC Meeting on Pfizer COVID-19 Vaccines for Children 6 months through 4 years
 - February 15, 2022, 5:30AM 2PM (8:30AM 5:00PM ET)



COVID-19 is a Childhood Illness

- 4x more deaths than flu
- 11x higher risk of hospitalization for unvaccinated children
- Poorest neighborhoods are far behind
- 65% of kids not vaccinated

MAKE NO MISTAKE COVID-19 IS A CHILDHOOD ILLNESS **COVID-19 CAN BE SERIOUS FOR KIDS. 4X MORE DEATHS** 11X HIGHER RISK OF HOSPITALIZATION THAN FLU COVID-19 associated hospitalizations in unvaccinated children are 11x higher than fully vaccinated. 8.300 Children 12-17-years old DEATHS HOSPITALIZATIONS Unvaccinated Over 800 children About 1 in 3 children have died from hospitalized with COVID-19 in the US. COVID-19 in the US were admitted to the ICU. compared to approximately 200 pediatric similar to the rate flu deaths over the among adults. past two years. 8/10/21 9/10/21 10/10/21 11/10/21 PEDIATRIC VACCINATION COVERAGE IS LOW, ESPECIALLY FOR CALIFORNIA'S MOST VULNERABLE CHILDREN 65% OF KIDS POOREST NEIGHBORHOODS ARE FAR BEHIND NOT VACCINATED . Only about 21% of children in California's poorest neighborhoods are vaccinated against COVID-19 Over 65% of California children ages 5-11 years compared to 64% in wealthiest neighborhoods. have yet to receive I dose of COVID-19 vaccine, leaving most children vulnerable to Omicron and future variants likely to follow. Wealthiest **Poorest** Neighborhoods Neighborhoods Vaccinate Children, ages 5-11 (as of January 26, 2022).

California COVID-19 Vaccination Program



Top 5 Reason to Get Kids Vaccinated



Unvaccinated children are at risk of getting COVID-19, + potential serious complications, and/or long-term impacts.



The vaccine is safe and effective, and no long-term problems have been seen for any vaccine.



Getting those who are eligible vaccinated can help keep schools & communities safe.



Getting them safely back to the classroom and their favorite afterschool activities

supports mental health & wellness.



Vaccines are safe, effective, and free





California's COVID-19 Vaccination Program Prevented >1.5 million COVID-19 Cases

Table 1: Comparison of primary and alternative model to estimate the number of COVID-19 cases averted due to vaccination in California by age group

	Age group (years)	Observed cases	Predicted COVID-19 cases (95% PI or UI)	Averted COVID-19 cases (95% PI or UI)	Relative reduction in % (95% PI or UI)
Primary model	Total (≥12)	2,983,152	4,506,630 (3,959,910, 5,071,680)	1,523,500 (976,800, 2,230,800)	34 (25, 43)
	12-17	238,031	278,960 (268,300, 290,120)	40,930 (30,270, 52,090)	15 (11, 18)
	18-49	1,829,625	2,866,350 (2,444,720, 3,412,980)	1,036,700 (615,100, 1,588,300)	36 (25, 46)
	50-64	588,553	894,900 (810,040, 1,003,720)	306,300 (221,500, 415,200)	34 (27, 41)
	≥65	326,943	466,410 (436,850, 507,170)	139,500 (109,900, 180,200)	30 (25, 36)

- Modeling study using CDPH data through October 2021
- Vaccination contributed to >30% reduction in COVID-19 cases.
- Study estimated direct effects of vaccination; overall impact of vaccination likely greater when indirect effects are considered



COVID-19 mRNA Vaccine VE vs ED/UC Encounters

TABLE 2. mRNA COVID-19 vaccine effectiveness* against laboratory-confirmed COVID-19–associated[†] emergency department and urgent care encounters and hospitalizations among adults aged ≥18 years, by number and timing of vaccine doses[§] — VISION Network, 10 states, ¶ August 2021–January 2022**

Characteristic	Total	SARS-CoV-2 positive test result no. (%)	VE fully adjusted % (95% CI)*	Waning trend p value ^{††}
ED/UC encounters				
Omicron-predominant period Unvaccinated (Ref)	24,799	13,991 (56)	_	_
Any mRNA vaccine, 2 doses <2 mos	19,822 555	8,351 (42) 157 (28)	41 (38–43) 69 (62–75)	<0.001
2–3 mos 4 mos	1,982 1,234	785 (40) 509 (41)	50 (45–55) 48 (41–54)	
≥5 mos Any mRNA vaccine, 3 doses	16,051 10,931	6,900 (43) 1,938 (18)	37 (34–40) 83 (82–84)	<0.001
<2 mos 2–3 mos	4,993 5,217	710 (14) 986 (19)	87 (85–88) 81 (79–82)	
4 mos ≥5 mos	692 29	224 (32) 18 (62)	66 (59–71) 31 (–50–68)	

Booster protection against Omicron ED/UC encounters wanes over time



COVID-19 mRNA Vaccine VE vs Hospitalization

TABLE 2. mRNA COVID-19 vaccine effectiveness* against laboratory-confirmed COVID-19–associated[†] emergency department and urgent care encounters and hospitalizations among adults aged ≥18 years, by number and timing of vaccine doses[§] — VISION Network, 10 states, ¶ August 2021–January 2022**

Characteristic	Total	SARS-CoV-2 positive test result no. (%)	VE fully adjusted % (95% CI)*	Waning trend p value ^{††}
ED/UC encounters				
Omicron-predominant period Unvaccinated (Ref)	3,911	1,890 (48)	_	_
Any mRNA vaccine, 2 doses	3,619 88	979 (27) 22 (25)	55 (50–60) 71 (51–83)	0.01
2–3 mos 4 mos	294 150	69 (23) 42 (28)	65 (53–74) 58 (38–71)	
≥5 mos Any mRNA vaccine, 3 doses	3,087 2,833	846 (27) 276 (10)	54 (48–59) 88 (86–90)	<0.001
<2 mos 2–3 mos	1,261 1,383	103 (8) 137 (10)	91 (88–93) 88 (85–90)	
≥4 mos	189	36 (19)	78 (67–85)	

Booster protection against Omicron hospitalization wanes over time, but remains higher than VE vs ED/Urgent Care encounters and VE vs infection




COVID-19 Booster Safety

- 82.6 million U.S. residents 18+ received a booster as of 2/6/22
- V-safe analysis:
 - N=721,562 booster recipients
 - 89% reported homologous COVID-19 mRNA vaccination
 - Local and systemic reactions less frequent following booster compared to dose 2
- VAERS analysis:
 - 39,286 reports of adverse events following booster dose
 - 92.4% of reports were non-serious
 - 37 reports of myocarditis



Local and systemic reactions *less frequent* following booster compared to dose 2





Myocarditis Following COVID-19 Booster


	No. of cases (rates)*,§ Rate: cases per 1 million doses adm				
	Pfizer-BioNTech (n = 18)		Moderna (n = 18)		
Age group, yrs	Men (n = 16)	Women (n<5)	Men (n = 10)	Women (n = 8)	
18-24	5 (4.1)	<5 (<1.0)	6 (8.7)	<5 (1.1)	
25–29	<5 (1.1)	0 (—)	<5 (3.2)	<5 (1.2)	
30–39	<5 (1.7)	<5 (<1.0)	<5 (<1.0)	<5 (1.5)	
40-49	0 (—)	0 (—)	0 (—)	<5 (<1.0)	
50-64	<5 (<1.0)	0 (—)	0 (—)	<5 (<1.0)	
≥65¶	5 (<1.0)	0 (—)	<5 (<1.0)	0 (—)	


- Myocarditis rate highest among males 18to-24 who received a Moderna booster:
 - 8.7 cases per 1 million doses
- Myocarditis rate among males 18-to-24 after dose #2 of Moderna primary series:
 - 40.0 cases per 1 million doses
 - Reference: ACIP 2/4/22



Updated Clinical Consideration for Use of COVID-19 Vaccines

Interim Clinical Considerations for Use of COVID-19 Vaccines Currently Approved or Authorized in the United States





Summary of recent changes (last updated February 11, 2022):

Updated Clinical Consideration for Use of COVID-19 Vaccines

Summary of recent changes (last updated February 11, 2022):

- Updated guidance for moderately or severely immunocompromised people
 - Clarification of existing recommendation to receive a 3-dose mRNA vaccine primary series followed by a booster dose for a total of 4 doses
 - New guidance to shorten the interval between completion of the mRNA vaccine primary series and the booster dose to at least 3 months (instead of 5 months)
 - New guidance for those who received the Janssen COVID-19 Vaccine primary series to receive an additional dose and a booster dose, for a total of 3 doses to be up to date
- Updated guidance that it is no longer necessary to delay COVID-19 vaccination following receipt of monoclonal antibodies or convalescent plasma
- · Updated guidance on receiving a booster dose if vaccinated outside the United States
- Updated contraindication and precaution section to include history of myocarditis or pericarditis after an mRNA COVID-19 vaccine as a precaution
- Reorganized and condensed multiple sections



Provider Office Hours Q&A

During today's session, please use the **Q&A panel** to ask your questions so our subject matter experts can respond directly.







Storage & Handling

Kate McHugh, CDPH



Provider Concern: Vaccine Wastage

- <u>Concern</u>: Wasting vaccines, especially if a vial is punctured to vaccinate a single patient.
- Response: Vaccine wastage is expected, may be unavoidable, and will increase as vaccine rollout continues because
 - more providers, including smaller provider sites, are now receiving vaccine;
 - vaccine continues to be available only as multi-dose vials; and
 - vials must often be punctured without using the full number of doses printed on the label.

<u>CDC Guidance</u>: Vaccinate every eligible person who presents at a vaccination site—even if it means puncturing a vial at the end of the day.

- Avoid missed opportunities for vaccination
- •Vaccinate family members or friends who accompany patients to medical visits even if they are not established patients at the practice.
- •Follow clinical best practices to maximize vaccination
 - Assess immunization status at every visit
 - Make a strong recommendation for immunization



Pfizer Internal Stability Data

- Pfizer 1170 (12+ years, purple cap): medical information
- Pfizer Tris-sucrose (12+ years, gray cap): medical information
- Pfizer pediatric (5-11 years, orange cap): medical information
- Pfizer Digital Assistant: <u>Search Medical Information | Pfizer Medical</u> Information - US
- This information can help you find quick answers to temperature excursions
- If you have difficulty interpreting, you can contact CDPH or Pfizer



Purple Cap Internal Data Example – Please review sheets linked (previous slide) for real temperature excursion

-90°C to -60°C (-130°F to -76°F)	 Expiration date of 9 months from date of manufacture, or 3 additional months from the 6 month expiration date printed on the vials and cartons, applies when product is stored from -96°C to -60°C (-141°F to -76°F). This applies to lots with expiration dates after 30 APR 2021. Vaccine can be used up to the revised expiry date noted in the authorized EUA Prescribing Information below. Vials with expiration dates after 31 March 2022 already reflect the 9 month expiry date. Total Time: 9 months + 1 week (expiration date of 9 months described in the EUA Prescribing Information plus 1 week of excursion time when product is stored between -96°C (-141°F) and -60°C (-76°F)). Pfizer has determined that no instability is expected at temperatures colder than -60°C (-76°F).
- 60°C to -25°C (-76°F to -13°F)	 There is no labeled/recommended time allowable in this temperature range. Any excursion time in this temperature range counts against the 2-week labelled time allowance at -25°C to -15°C (-13°F to 5°F). If vials are stored in a freezer set to temperatures between -60°C (-76°F) and -25°C (-13°F), this may be considered comparable to storage at -25°C to -15°C (-13°F to 5°F).
-25°C to -15°C (-13°F to 5°F)	 Total Time: 17 days = 2 weeks [14 days] labeled time described in the Prescribing Information plus 3 days of excursion time. The time of storage at -25°C to -60°C (-13°F to -76°F) and any time used for transportation at -25°C to -15°C (-13°F to 5°F) count against this time.
-15°C to -3°C (5°F to 26°F)	 There is no labeled time allowable in this temperature range. Total Time: 72 hours of excursion time (see <u>Freeze/Thaw</u> section for additional details related to excursions in this range)



Pfizer Pediatric (6 months – 4 years, Maroon Cap)

- Allows Pfizer more time to manufacture vaccine
- CDPH has more time to prepare and educate providers!
- COVID-19 Vaccine Product Guide (eziz.org)
- Small orders: CDPH plans to have the Third-party redistributor (TPR) distribute the vaccine within a few weeks after it is approved.



Janssen (J&J) Shelf-life Extension

- J&J has requested a shelf-life extension for its Janssen vaccine
 - 5 months
 - FDA expected to announce ruling this month
 - Don't dispose of your Janssen yet.
- What's in it for you?
 - No additional federal purchase/no biweekly threshold
 - Shelf-life extension provides a limited supply of Janssen through the summer
 - Once again, don't dispose of your Janssen yet.



Vaccine Management

Eric Norton, My Turn and Claudia Aguiluz, CDPH



New Walk-In Only Clinic Setup Process

The process for creating a Walk-In Only Clinic on My Turn has changed as of 2/3. If you are creating a new Walk-In Only Clinic or if you update the Close Date value of an old Walk-In Only Clinic, please follow this new process.

Please reference this \(\bigcup \) Knowledge Center Article to familiarize yourself with the new process!



Bulk Upload Feature Uses in My Turn



You can use the Bulk Walk-In Upload feature to **upload appointments that occurred before your Organization was enrolled** to ensure they are recorded in CAIR2.



You can use the Bulk Walk-In Upload feature to upload appointments that occurred while you were mobile, or offline.




Please use the Bulk Upload feature, which can be accessed $\frac{Q}{Q}$ here in My Turn.

How to Execute a Bulk Upload in My Turn

- The Bulk Walk-In Upload Page is your one-stop shop for Bulk Uploads! You can download the file and re-upload in the same place.
 - ✓ Step 1: Select "More" and choose "Bulk Walk-In Upload" from the dropdown.
 - ✓ Step 2: Follow the steps on the Bulk Walk-In Upload Page to execute.

Please use the Bulk Upload feature, which can be accessed <a> here in My<a> Turn.





Pfizer Pediatric (6 months – 4 years) Product Update



The FDA Emergency Use Authorization (EUA) *has been postponed* at Pfizer's request.



They are looking at implementing a 3-dose series and expanding testing.



Future waves will be put on hold for now. Provider Standard Orders for this product will not be opened.



President's Day


- The COVID-19 Provider Call Center will be closed on Monday, February 21, 2022.
- Place your orders on or before Monday, February 21.

Presidents' Day Holiday Ordering & Delivery Cadence-Updated 2/14/22 Monday Tuesday Wednesday Thursday Friday February 14 15 16 17 18 Order ahead if not working on February 21 25 February 21 22 23 24 Submit order by 5pm Submit Catch-Up Orders by 5pm Moderna/J&J Deliveries Back to routine delivery schedule No vaccine deliveries on the Presidents' Day holiday Pfizer Deliveries LHD/MCE Approval by 12pm LHD/MCE Approval by 12pm Order deadlines No deliveries Adjusted delivery dates Delivery windows are dependent on provider's days/hours of operation. Update hours in myCAvax for any holiday closures. Once submitted, orders cannot be cancelled. Watch for emails regarding order confirmations, advance shipment notices of vaccine and ancillary kits, and temperature monitoring alerts.



Orders and Deliveries Next Week

Monday	Tuesday	Wednesday	Thursday	Friday
February 14	15	16	17	18
			Order ahead if not working on February 21	
February 21	22	23	24	25
Submit order by 5pm		Submit Catch-Up Orders by 5pm		
No vaccine deliveries on the Presidents' Day holiday	Moderna/J&J Deliveries			Back to routine delivery schedule
	Pfizer Deliveries			
		LHD/MCE Approval by 12pm		LHD/MCE Approval by 12pm




No deliveries

Adjusted delivery dates




Early Access: Brand-New Vaccine Ordering Screen



We anticipate launching access for all Providers to the updated Vaccine Order screen with multi-line ordering, including updates made with the feedback provided throughout Phase 1.


Early Access: Order Feedback

Early Access Providers may request vaccine using the new interface and leave feedback after every order. If you haven't provided feedback yet, please let us know your thoughts!





Early Access: Ancillary Kit Opt-Out



✓ Early Access Providers may opt-out of Ancillary Kits related to Small Order requests.

To Opt-Out, use the Pick List to select Opt-Out of Ancillary Kits.

Reminder: You can opt-out for all products EXCEPT Pfizer.



APPENDIX



myCAvax – Known Issues - *Updated 2/10*



Org Coordinators Missing from Related Contacts on a Provider Location

We will address an issue that allows for some Community Users to not be able to see all of their Location's Waste Events and Shipments.

Unable to Reject Standard or Small Orders if Product Configuration Changes

✓ We are investigating an issue where pending orders for a product made ineligible/inactive are not able to be rejected from 'Vaccine Order Review'.



✓ Fix: 2/24/2022

- Fix: TBD
- ✓ In the meantime, we recommend rejecting orders from the Order's 'Order' > 'Details', if you are unable to reject from 'Vaccine Order Review'.



Wrap-up

Leslie Amani, CDPH



Additional Support

Type of S	Support	Description	Updated 12.29.21
	COVID-19 Provider Call Center	The COVID-19 Call Center for Providers and Local Health Departments is dedicated to medical provide their COVID-19 response, specifically addressing questions about State program requirements, enrolled distribution, including the Vaccine Marketplace.	
/ • \		Email: covidcallcenter@cdph.ca.gov	
		Phone: (833) 502-1245, Monday through Friday from 8AM–6PM	
	Enrollment Support	For Provider enrollment support, please contact myCAvax Clinic Operations at	
	• •	Email: myCAvaxinfo@cdph.ca.gov	
		Dedicated staff provide up-to-date information and technical support on the myCAvax system.	
لباح	myCAvax Help Desk	Email: myCAvax.HD@Accenture.com	
\Box		 Phone: (833)-502-1245, option 3, Monday through Friday 7AM–7PM, Saturday and Sunday 8AM-1F 	PM
		For training opportunities: https://eziz.org/covid/education/	
	My Turn Clinic Help Desk	For onboarding support (those in the process of onboarding): myturnonboarding@cdph.ca.gov	
	my furth diffice field beak	For technical support with My Turn Clinic for COVID-19 and flu vaccines: MyTurn.Clinic.HD@Accent	ure.com or
\Box		(833) 502-1245, option 4: Monday through Friday 7AM-7PM, Saturday and Sunday 8AM-1PM.	
		For job aids, demos, and training opportunities: flu at https://eziz.org/covid/myturn/flu/ and COVID at https://exiz.org/covid/myturn/flu/ and COVID at https://exiz.org/ and	



Hear it? Clear It.

If you see or hear of any vaccine-related rumors within the communities you serve, share them with our Trust and Safety team via the CDPH Rumors Inbox.



Trust and Safety Team

Our shared mission is to reduce COVID-19 vaccine hesitancy and increase vaccination across the State of California.



How You Can Help

You are critical in our effort to provide Californians accurate and timely information around COVID-19 vaccination.



Monitor What You See and Hear

Monitor online media and what you hear in your local communities for potential rumors and inaccurate information.

If found, report it to rumors@cdph.ca.gov

Contact



Provider Office Hours Q&A

During today's session, please use the **Q&A panel** to ask your questions so our subject matter experts can respond directly.







Thank you!



Monday:

My Turn myCAvax Office Hours
Zoom Link

Monday, February 21-Canceled

Next session: Monday, February 28, at

12:00 PM

Friday:

Provider Office Hours

Next session: Friday, February 25, 9AM

Audio Conference: Register to access

Session Password: Immunize!

Thank you to Provider Office Hours' Planning Team: Leslie Amani, Rachel Jacobs, Hailey Ahmed, Blanca Corona, and Reva Anderson.

